Bifogade filer
Kurs & Likviditet
Kalender
2024-10-30 | Kvartalsrapport 2024-Q3 |
2024-08-01 | Kvartalsrapport 2024-Q2 |
2024-05-08 | Kvartalsrapport 2024-Q1 |
2024-05-01 | Ordinarie utdelning BIOPOR 0.00 DKK |
2024-04-30 | Årsstämma 2024 |
2024-04-04 | Bokslutskommuniké 2023 |
2023-11-01 | Kvartalsrapport 2023-Q3 |
2023-08-01 | Kvartalsrapport 2023-Q2 |
2023-05-10 | Kvartalsrapport 2023-Q1 |
2023-04-28 | Ordinarie utdelning BIOPOR 0.00 DKK |
2023-04-27 | Årsstämma 2023 |
2023-03-30 | Bokslutskommuniké 2022 |
2022-11-23 | Extra Bolagsstämma 2022 |
2022-11-09 | Kvartalsrapport 2022-Q3 |
2022-08-17 | Kvartalsrapport 2022-Q2 |
2022-05-11 | Kvartalsrapport 2022-Q1 |
2022-04-04 | Ordinarie utdelning BIOPOR 0.00 DKK |
2022-04-01 | Årsstämma 2022 |
2022-03-10 | Bokslutskommuniké 2021 |
2021-11-17 | Kvartalsrapport 2021-Q3 |
2021-11-15 | Extra Bolagsstämma 2021 |
2021-08-18 | Kvartalsrapport 2021-Q2 |
2021-05-12 | Kvartalsrapport 2021-Q1 |
2021-05-03 | Ordinarie utdelning BIOPOR 0.00 DKK |
2021-04-29 | Årsstämma 2021 |
2021-03-17 | Bokslutskommuniké 2020 |
2020-11-18 | Kvartalsrapport 2020-Q3 |
2020-08-19 | Kvartalsrapport 2020-Q2 |
2020-05-07 | Kvartalsrapport 2020-Q1 |
2020-04-14 | Årsstämma 2020 |
2020-03-20 | Ordinarie utdelning BIOPOR 0.00 DKK |
2020-03-11 | Bokslutskommuniké 2019 |
2019-11-21 | Kvartalsrapport 2019-Q3 |
2019-08-15 | Kvartalsrapport 2019-Q2 |
2019-05-09 | Kvartalsrapport 2019-Q1 |
2019-03-19 | Ordinarie utdelning BIOPOR 0.00 DKK |
2019-03-18 | Årsstämma 2019 |
2019-02-22 | Bokslutskommuniké 2018 |
2018-11-08 | Kvartalsrapport 2018-Q3 |
2018-08-16 | Kvartalsrapport 2018-Q2 |
2018-05-03 | Kvartalsrapport 2018-Q1 |
2018-04-16 | Ordinarie utdelning BIOPOR 0.00 DKK |
2018-04-13 | Årsstämma 2018 |
2018-03-08 | Bokslutskommuniké 2017 |
2017-11-07 | Kvartalsrapport 2017-Q3 |
2017-05-04 | Kvartalsrapport 2017-Q1 |
2017-04-24 | Ordinarie utdelning BIOPOR 0.00 DKK |
2017-04-21 | Årsstämma 2017 |
2017-03-15 | Bokslutskommuniké 2016 |
2016-11-03 | Kvartalsrapport 2016-Q3 |
2016-08-04 | Kvartalsrapport 2016-Q2 |
2016-05-04 | Kvartalsrapport 2016-Q1 |
2016-04-15 | Ordinarie utdelning BIOPOR 0.00 DKK |
2016-04-14 | Årsstämma 2016 |
2016-03-16 | Bokslutskommuniké 2015 |
2015-11-06 | Kvartalsrapport 2015-Q3 |
2015-08-10 | Kvartalsrapport 2017-Q2 |
2015-08-07 | Kvartalsrapport 2015-Q2 |
2015-05-05 | Kvartalsrapport 2015-Q1 |
2015-04-13 | Ordinarie utdelning BIOPOR 0.00 DKK |
2015-04-10 | Årsstämma 2015 |
2015-03-18 | Bokslutskommuniké 2014 |
2014-11-07 | Kvartalsrapport 2014-Q3 |
2014-08-08 | Kvartalsrapport 2014-Q2 |
2014-05-06 | Kvartalsrapport 2014-Q1 |
2014-04-11 | Ordinarie utdelning BIOPOR 0.00 DKK |
2014-04-10 | Årsstämma 2014 |
2014-03-19 | Bokslutskommuniké 2013 |
2013-11-08 | Kvartalsrapport 2013-Q3 |
2013-08-02 | Kvartalsrapport 2013-Q2 |
2013-05-07 | Kvartalsrapport 2013-Q1 |
2013-04-17 | Ordinarie utdelning BIOPOR 0.00 DKK |
2013-04-16 | Årsstämma 2013 |
2013-03-19 | Bokslutskommuniké 2012 |
2013-02-26 | Extra Bolagsstämma 2013 |
2012-11-20 | Kvartalsrapport 2012-Q3 |
2012-08-23 | Kvartalsrapport 2012-Q2 |
2012-05-25 | Kvartalsrapport 2012-Q1 |
2012-04-18 | Ordinarie utdelning BIOPOR 0.00 DKK |
2012-04-17 | Årsstämma 2012 |
2012-03-19 | Bokslutskommuniké 2011 |
2011-11-24 | Kvartalsrapport 2011-Q3 |
2011-08-25 | Kvartalsrapport 2011-Q2 |
2011-05-25 | Kvartalsrapport 2011-Q1 |
2011-04-07 | Årsstämma 2011 |
2011-03-17 | Ordinarie utdelning BIOPOR 0.00 DKK |
2010-04-21 | Ordinarie utdelning BIOPOR 0.00 DKK |
Beskrivning
Land | Danmark |
---|---|
Lista | Small Cap Copenhagen |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
November 3, 2021
Announcement no. 19
Update on Patient Enrollment for Pivotal Study of NGAL in Pediatrics
COVID-19 has continued to impact hospital operations and BioPorto’s enrollment of pediatric patients to be evaluated for moderate to severe acute kidney injury (AKI).
With the goal of optimizing the ongoing pediatric clinical trial’s statistical power for the upcoming submission to the US Food and Drug Administration (FDA), BioPorto A/S (BioPorto) has decided to continue patient enrollment beyond its original goal of December 31, 2021, into the first half of 2022.
“Despite our strong focus on engaging with the participating clinics, enrollment has been slower than planned as COVID-19 still affects the health care sector. Based on actual enrollment figures and the outlook on COVID-19, we have revised our enrollment forecast and now expect to finish data collection in the first half of 2022,” said Christopher Bird, Chief Medical Officer at BioPorto.
After enrollment is complete, BioPorto will continue to work interactively with the FDA to submit a De Novo Classification Request, as the NGAL Test maintains its Breakthrough Designation status.
This announcement does not alter BioPorto’s financial guidance for 2021 as most recently presented in the Interim Report for Second Quarter 2021.
For further information, please contact:
Chris Bird, Chief Medical Officer, BioPorto A/S, +1 858 868 1814
Tim Eriksen, Investor relations, BioPorto A/S, +45 61 68 77 79
Email: investor@bioporto.com
About BioPorto
BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].